RO4929097联合贝伐珠单抗治疗复发性恶性胶质瘤的I期研究
在复发性恶性胶质瘤受试者中开展I期临床试验,评估RO4929097联合贝伐珠单抗的安全性和最大耐受剂量。共入组13例受试者,因制造商决定停止药物生产而未确定最大耐受剂量。12例可评估受试者中2例出现影像学缓解,中位总生存期10.9个月,中位无进展生存期3.7个月。
要点
- RO4929097联合贝伐珠单抗在复发性恶性胶质瘤中耐受性良好
- 因制造商停止药物生产,未确定RO4929097联合贝伐珠单抗的最大耐受剂量
- 12例可评估受试者中2例出现影像学缓解,中位总生存期10.9个月
核心结论
- RO4929097联合贝伐珠单抗耐受性良好;鉴于有力的科学依据,应考虑开展抗血管生成与notch信号通路抑制剂的进一步研究。
研究设计与样本
- 通过成人脑肿瘤联盟开展的I期临床试验,纳入复发性恶性胶质瘤受试者,共入组13例。
- 主要目标为评估安全性和确定RO4929097联合贝伐珠单抗的最大耐受剂量。
- 次要目标为确定总生存期、无进展生存期、影像学缓解、药代动力学评价和组织生物标志物分析。
主要发现
- 接受最高剂量RO4929097治疗的3例受试者中,观察到1例3级毒性和1例2级毒性。
- 12例可评估受试者中2例出现影像学缓解,其中1例完全缓解,1例部分缓解。
- 中位总生存期为10.9个月,中位无进展生存期为3.7个月;2例受试者在治疗开始后6个月时无疾病进展。
- 药代动力学评价未发现具有临床意义的药物相互作用;所有分析的组织标本均显示notch信号通路激活。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因制造商决定停止药物生产,未能确定RO4929097联合贝伐珠单抗的最大耐受剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiangiogenic therapies for malignant gliomas often result in transient response, and recurrent disease is characterized by adoption of invasive and hypoxic phenotype. The notch signaling pathway is activated in gliomas, and augments cell migration and hypoxic response. Here we report a clinical study of the combination of bevacizumab and RO4929097, an inhibitor of the notch signaling cascade. A phase I clinical trial was conducted through the Adult Brain Tumor Consortium in subjects with recurrent malignant glioma. Primary objectives were to assess safety and to define the maximum tolerated dose of RO4929097 in combination with bevacizumab. Secondary objectives were to determine overall survival, progression free survival, radiographic response, pharmacokinetic evaluation, and tissue biomarker analysis. Thirteen subjects were enrolled. Of the three subjects treated with the highest dose of RO4929097, one grade 3 toxicity and one grade 2 toxicity were observed. Definitive maximum tolerated dose of RO4929097 in combination with bevacizumab was not identified due to manufacturer's decision to halt drug production. 2 of 12 evaluable subjects demonstrated radiographic response; one subject experienced CR and the second PR. The median overall survival was 10.9 months with a median progression-free survival of 3.7 months. Two subjects remained free of disease progression at 6 months from treatment initiation. PK evaluation did not identify clinically significant drug-drug interactions. All analyzed tissue specimens revealed activation of notch signaling. Combination of RO4929097 and bevacizumab was well-tolerated. Given the compelling scientific rationale, additional studies of antiangiogenic and notch signaling inhibitors should be considered.
引用
- Pan E, Supko JG, Kaley TJ, et al. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016. PMID: 27826680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。